Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs

Journal of Drug Targeting

Volumn 6, Issue 1, 1998, Pages 17-36

  Marttin, E ^a   Verhoef, J C ^a   Merklus, F W H M ^a  

^a NONE

Author keywords

Cyclodextrins; Intranasal administration; Methylated cyclodextrin derivatives; Peptide and protein drugs

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; BENZALKONIUM CHLORIDE; BUSERELIN; CALCITONIN; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; GLUCAGON; LEUPRORELIN; PENETRATION ENHANCING AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAURODIHYDROFUSIDATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CHEMICAL STRUCTURE; CILIARY MOTILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; HEMOLYSIS; INTRANASAL DRUG ADMINISTRATION; MASS SPECTROMETRY; MEMBRANE PERMEABILITY; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TIGHT JUNCTION;

EID: 0031771926     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869808997878     Document Type: Review

References (97)

1. Adjei, A., Sundberg, D., Miller, J. and Chun, A. (1992) Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res., 9, 244-249.
2. Albers, E. and Müller, B.W. (1995) Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carr. Syst., 12, 311-337.
3. Anderberg, E.K., Lindmark, T. and Artursson, P. (1993) Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res., 10, 857-864.
4. Antlsperger, G. and Schmid, G. (1996) Toxicological comparison of cyclodextrins. In: Szejtli, J. and Szente, L. (eds.) Proceedings of the Eighth International Symposium On cylcodextrins (Dordrecht: Kluwer Academic Publishers), pp. 149-155.
5. Brewster, M.E., Hora, M.S., Simpkins, J.W. and Bodor, N. (1991) Use of 2-hydroxyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res., 8, 792-795.
6. Chien, Y.W. and Banga, A.K. (1989) Potential developments in systemic delivery of insulin. Drug Dev. Ind. Pharm., 15, 1601-1634.
7. Drejer, K., Vaag, A., Bech, K., Hansen, P., Sorensen, A.R. and Mygind, N. (1992) Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects. Diabet. Med., 9, 335-340.
8. Duchêne, D. and Wouessidjewe, D. (1990a) Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev. Ind. Pharm., 16, 2487-2499.
9. Duchêne, D. and Wouessidjewe, D. (1990b) Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives. Pharm. Technol. Int., June, 21-29.
10. Ennis, R.D., Borden, L. and Lee, W.A. (1990) The effects of permeation enhancers on the surface morphology of the rat nasal mucosa: A scanning electron microscopy study. Pharm. Res., 7, 468-475.
11. Forbes, A.R. and Gamsu, G. (1979) Mucociliary clearance in canine lung during and after general anesthesia. Anesthesiology, 50, 26-29.
12. Frank, D., Gray, J.E. and Weaver, R.N. (1976) Cyclodextrin nephrosis in the rat. Am. J. Pathol., 83, 367.
13. Frijlink, H.W., Eissens, A.C., Hefting, N.R., Poelstra, K., Lerk, C.F. and Meijer, O.K.F. (1991) The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res., 8, 9-16.
14. Garay, R.P., Feray, J.C., Nazaret, C. Fanons, K., Villegas, M.J. and Letavernier, J.F. (1994) A new approach for the in vitro evaluation of cyclodextrin effects on cellular membranes of human cells. In: Osa, T. (ed.) Proceedings 7th International Cyclodextrin Symposium (Tokyo: Komiyama Printing Co.). pp. 373-376.
15. Gizurarson, S. (1993) The relevance of nasal physiology to the design of drug absorption studies. Advan. Drug Del. Rev. 11, 329-347.
16. Haeberlin, B., Gengenbacher, T., Meinzer, A. and Fricker, G. (1996) Cyclodextrins Useful excipients for oral peptide administration? Int. J. Pharm., 137, 103-110.
17. Hermens, W.A.J.J., Hooymans, P.M., Verhoef, J.C. and Merkus, F.W.H.M. (1990) Effects of absorption enhancers on human nasal tissue ciliary movement in vitro. Pharm. Res., 7, 144-146.
18. Hermens, W.A.J.J., Beider, C.W.J., Merkus, J.M.W.M., Hooymans, P.M., Verhoef, J. and Merkus, F.W.H.M. (1991) Intranasal estradiol administration to oophorectomized women. Eur J. Ohstet. Gynecol. Reprod. Biol., 40, 35-41.
19. Hermens, W.A.J.J., Belder, C.W.J., Merkus, J.M.W.M., Hooymans, P.M., Verhoef, J. and Merkus, F.W.H.M. (1992) Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol., 43, 65-70.
20. Hilsted, J., Madsbad, S., Hvidberg, A., Rasmussen, M.H., Krarup, T., Ipsen, H., Hansen, B., Pedersen, M., Djurup, R. and Oxenboll, B. (1995) Intranasal insulin therapy: The clinical realities. Diabetologica, 38, 680-684.
21. Hochman, J.H., Fix, J.A. and LeCluyse, E.L. (1994) In vitro and in vivo analysis of the mechanism of absorption enhancement by palmityolcarnitine. J. Pharmacol. Ex. Ther., 269, 813-821.
22. Hosoya, K.I., Kubo, H., Natsume, H., Sugibayashi, K., Morimoto, Y. and Yamashita, S. (1993) The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits. Biopharm. Drug Disp., 14, 685-696.
23. Hovgaard, L. and Bronsted, H. (1995) Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancers effects of cyclodextrins. Pharm. Res., 12, 1328-1332.
24. Illum, L. (1996) Nasal delivery. The use of animal models to predict performance in man. J. Drug Targ., 3, 427-442.
25. Ilium, L. and Davis, S. (1992) Intranasal insulin: clinical pharmacokinetics. Clin. Pharmacokinet., 23, 30-41.
26. Irie, T., Wakamatsu, K., Arima, H., Aritomi, H. and Uekama, K. (1992) Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm., 84, 129-139.
27. Irwin, W.J., Dwivedi, A.K., Holbrook, P.A. and Dey, M.J. (1994) The effect of cyclodextrins on the stability of peptides in nasal enzymic systems. Pharm. Res., 11, 1698-1703.
28. Jabbal Gill, I., Fisher, A.N., Hinchcliffe, M., Whetstone, J., Farraj, N., De Ponti, R. and Ilium, L. (1994) Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane. Eur. J. Pharm. Sci., 1, 237-248.
29. Jacobs, M.A., Schreuder, R.H., Jap-A-Joe, K., Nauta, J.J., Andersen, P.M. and Heine, R.J. (1993) The pharmacodynumics and activity of intranasally administered insulin in healthy male volunteers. Diabetes, 42, 1649-1655.
30. Jodál, I., Nánási, P. and Szejtli, J. (1988) Investigation in the hemolytic effect of the cyclodextrin derivatives. In: Huber, O. and Szejtli, J. (eds.) Proceedings of the Fourth International Symposium on Cyclodextrins (Dordrecht: Kluwer Academic Publishers), pp. 407-413.
31. Kagatani, S., Shinoda, T., Fukui, M., Ohmura, T., Hasumi, S. and Sonobe, T. (1996) Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm. Res., 13, 739-743.
32. Kilsdonk, E.P.C., Yancey, P.G., Stoudt, G.W., Bangerter, F.W., Johnson, W.J., Phillips, M.C. and Rothblat, G.H. (1995) Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem., 270, 17250-17256.
33. Koizumi, K., Okada, Y., Kuboza, Y. and Utamura, T. (1987) Inclusion complexes of poorly water-soluble drugs with glycosyl-cyclodextrins. Chem. Pharm. Bull., 35, 3413-3418.
34. Krishnamoorthy, R., Wolka, A.M., Shao, Z. and Mitra, A.K. (1995) Cyclodextrins as mucosal absorption promoters IV. Evaluation of nasal mucotoxicity. Eur. J. Pharm. Biopharm., 41, 296-301.
35. Landa, J.F., Hirsch, J.A. and Lebeaux, M.I. (1975) Effects of topical and general anesthetics on tracheal mucuos velocity in sheep. J. Appl. Physiol. 38, 946-948.
36. Lee, W. A. (1990) Permeation enhancers for the nasal delivery of protein and peptide therapeutics. Biopharm. Drug Disp., Nov/ Dec. 22-25.
37. Lee, W.A., Narog, B.A., Patapoff, T.W. and Wang, Y.J. (1991) Intranasal bioavailability of insulin powder formulations: Effect of permeation enhancer to protein ratio. J. Pharm. Sci., 80, 725-729.
38. Leroy-Lechat, F., Skiba, M., Wouessidjewe, D. and Duchêne, D. (1992) Cytotoxicity of cyclodextrins and derivatives. In: Hedges, A.R. (ed.)Minutes of the 6th International Symposium on Cyclodextrins (Paris: Editions de Santé), pp. 292-297.
39. Leroy-Lechat, F., Wouessidjewe, D., Andreux, J.-P., Puisieux, F. and Duchêne, D. (1994) Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm., 101, 97-103.
40. Lovatt, M., Cooper, A. and Camilleri, P. (1996) Energetics of cyclodextrin-induced dissociation of insulin. In: Szejtli, J. and Szente, L. (eds.) Proceedings of the Eighth International Symposium on Cyclodextrins (Dordrecht: Kluwer Academic Publishers), pp. 361-364.
41. Marttin, E., Verhoef, J.C., Romeijn, S.G. and Merkus, F.W.H.M. (1995) Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm. Res., 12, 1151-1157.
42. Marttin, E., Verhoef, J.C., Romeijn, S.G., Zwart, P. and Merkus, F.W.H.M. (1996) Acute histopathological effects of benzalkonium chloride and absorption enhancers on rat nasal epithelium in vivo. Int. J. Pharm., 141, 151-160.
43. Marttin, E., Romeijn, S.G., Verhoef, J.C. and Merkus, F.W.H.M. (1997a) Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J. Pharm. Sci., 86, 802-807.
44. Marttin, E., Schipper, N.G.M., Verhoef, J.C. and Merkus, F.W.H.M. (1998) Nasal mucociliary clearance as a factor in nasal drug delivery. Advan. Drug Del. Rev., 29, 13-38.
45. Marttin, E., Verhoef, J.C., Cullander, C., Romeijn, S.G., Nagelkerke, J.F. and Merkus, F.W.H.M. (1997b) Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers Pharm. Res., 14, 631-637.
46. Matsubara, K., Abe, K., Irie, T. and Uekama, K. (1995) Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin. by cyclodextrin derivatives in rats. J. Pharm. Sci., 84, 1295-1300.
47. McMartin, C., Hutchinson, L.E.F., Hyde, R. and Peters, G.E. (1987) Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci., 76, 535-540.
48. Merkus, F.W.H.M., Verhoef, J., Romeijn, S.G. and Schipper, N.G.M. (1991a) Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm. Res., 8, 588-592.
49. Merkus, F.W.H.M., Verhoef, J., Romeijn, S.G. and Schipper, N.G.M. (1991b) Interspecies differences in the nasal absorption of insulin. Pharm. Res., 8, 1343.
50. Merkus, F.W.H.M., Schipper, N.G.M., Hermens, W.A.J.J., Romeijn, S.G. and Verhoef, J.C. (1993) Absorption enhancers in nasal drug delivery: efficacy and safety. J. Controlled Rel., 24, 201-208.
51. Merkus, F.W.H.M., Marttin, E., Romeijn, S.G. and Verhoef, J. (1996a) In situ perfusion is an unrealistic approach to assess the effects of absorption enhancers on nasal epithelium. Eur J. Pharm. Biopharm., 42, 159.
52. Merkus, F.W.H.M., Schipper, N.G.M. and Verhoef, J.C. (1996b) The influence of absorption enhancers on the intranasal insulin absorption in normal and diabetic subjects. J. Controlled Rel., 41, 69-75.
53. Moses, A.C., Gordon, G.S., Carey, M.C. and Fier, J.S. (1983) Insulin administered intranasally as an insulin-bile salt aerosol. Diabetes, 32, 1040-1047.
54. Nakamuta, H., Nitta, T., Hoshino, T. and Koida, M. (1996) Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect. Biol. Pharm. Bull, 19, 217-219.
55. Nakanishi, K., Nadai, T., Masada, M. and Miyajima, K. (1990) Effect of cyclodextrins on biological membrane. I. Effect of cyclodextrins on the absorption of a non-absorbable drug from the rat small intestine and rectum. Chem. Pharm. Bull., 38, 1684-1687.
56. Nakanishi, K., Masukawa, T. and Miyajima, K. (1994) The interaction with cyclodextrin and biological membrane on the drug absorption. In: Osa, T. (ed.) Proceedings 7th International Cyclodextrins Symposium (Tokyo: Komiyama Printing Co.), pp. 377-381.
57. Neufeld, E.B., Cooney, A.M., Pitha, J., Dawidowicz, E.A., Dwyert, N.K., Pentchev, P.F. and Blanchette-Mackie, E.J. (1996) Intracellular trafficking of cholesterol monitored with a cyclodextrin. J. Biol. Chem., 271, 21604-21613.
58. Nitta, T., Hoshino, T., Koida, M. and Nakmuta, H. (1996) Histomorphometrical evaluation of anti-osteopenic effect of nasal salmon calcitonin in type 1 osteoporotic model of rats. Biol. Pharm. Bull, 19, 214-216.
59. Nolte, M.S., Taboga, C., Salamon, E., Moses, A., Longenecker, J., Flier, J. and Karam, J.H. (1990) Biological activity of nasally administered insulin in normal subjects. Horm. Metabol. Res., 22, 170-174.
60. Ohtani, Y., Irie, T., Uekama, K., Fukunaga, K. and Pitha, J. (1989) Differentialeffectsofalpha-,beta-,andgamma-cyclodextrin on human erythrocytes. Eur. J. Biochem., 186, 17-22.
61. Okada, Y., Kubota, Y., Koizumi, K., Hizukuri, S., Ohfuji, T. and Ogata, K. (1988) Some properties and the inclusion behaviour of branched cyclodextrins. Chem. Pharm. Bull., 36, 2176-2185.
62. Olivier, P., Verwaerde, F. and Hedges, A.R. (1991) Subehronic toxicity of orally administered beta-cyclodextrin in rats. J. Am. Coll. Toxicol., 10, 407-419.
63. Perrin, J.H., Field, F.P., Hansen, D.A., Mufson, R.A. and Torosian, G. (1978) β-cyclodextrin as an aid to peritoneal dialysis. Renal toxicity of β-cyclodextrin in the rat. Res. Comm. Chem. Pathol. Pharmacol., 19, 373.
64. Pitha, J. (1991) Pharmacological role of hydroxypropyl cyclodextrins. In: Duchêne. D. (ed.) New Trends in Cyclodextrins and Derivatives (Paris: Editons de Santé), p. 353.
65. Pontiroli, A.E., Alberetto, M., Pajetta, E., Calderara, A. and Pozza, G. (1987) Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavalability and effectiveness in normal subjects. Diab. Metab., 13, 441-443.
66. Pontiroli, A.E., Calderara, A. and Pozza, G. (1989) Intranasal drug delivery; Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin. Pharmacokinet., 17, 299-307.
67. Rajewski, R.A. and Stella, V.J. (1996) Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci., 85, 1142-1169.
68. Reeuwijk, H.J.E.M., Irth, H., Tjaden, U.R., Merkus, F.W.H.M. and Van der Greef, J. (1993) Liquid chromatographic determination of β-cyclodextrin derivatives based on fluorescence enhancement after inclusion complexation. J. Chromatogr., 614, 95-101.
69. Romeijn, S.G., Verhoef, J.C., Marttin, E. and Merkus, F.W.H.M. (1996) The effect of nasal drug formulations on ciliary beating in vitro. Int. J. Pharm., 135, 137-145.
70. Sakr, F.M. (1996) Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations. Int. J. Pharm., 132, 189-194.
71. Schipper, N.G.M., Verhoef, J., Romeijn, S.G. and Merkus, F.W.H.M. (1992) Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning. J. Controlled Rel., 21, 173-186.
72. Schipper, N.G.M., Romeijn, S.G., Verhoef, J.C. and Merkus, F.W.H.M. (1993a) Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations. Pharm. Res., 10, 682-686.
73. Schipper, N.G.M., Verhoef, J.C., De Lannoy, L.M., Romeijn, S.G., Brakkee, J.H., Wiegant, V.M., Gispen, W.H. and Merkus, F.W.H.M. (1993b) Nasal administration of an ACTH(4-9) peptide analog with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Br. J. Pharmacol., 110, 1335-1340.
74. Schipper, N.G.M., Verhoef, J.C., Romeijn, S.G. and Merkus, F.W.H.M. (1995) Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Cacif. Tissue Int., 56, 280-282.
75. Shao, Z., Krishnamoorthy, R. and Mitra, A.K. (1992) Cyclodextrins as nasal absorption promoters of insulin mechanistic evaluations. Pharm. Res., 9, 1157-1163.
76. Silber, G., Proud, D., Warner, J., Nacleno, R., Kagey-Sobotka, A., Lichtenstein, L. and Eggleston, P. (1988) In vivo release of inflammatory mediators by hyperosmolar solutions. Rev. Respir. Dis., 137, 606-612.
77. Sim, T.C., Grant, A., Hilsmeier, K.A., Fukuda, Y. and Alam, R. (1994) Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am. J. Resp. Crit. Care Med., 149, 339-344.
78. Stadel, J.M., Hoyle, K., Naclerio, R.M., Roshak, A. and Chilton, F.H. (1994) Characterization of phospholipase A2 from human nasal lavage. Am. J. Respir. Cell Mol. Biol., 11, 408-413.
79. Strattan, C.E. (1991) Cyclodextrins and biological macromolecules. Biopharm, Nov/Dec, 44-51.
80. Szabo, P., Ferenczy, T., Seifövö, J. and Liptáp, A. (1982) Absorption and elimination of cyclodextrin derivatives by rabbits and rats. In: Szejtli, J. (ed.) Proceedings of the 1st International Symposium on Cyclodextrins (Dordrecht: Kluwer Academic Publishers), p. 115.
81. Szatmári, I. and Vargay, Z. (1988) Pharmacokinetics of dimethyl-β-cyclodextrin in rats. In: Huber, O. and Szejtli, J. (eds.) Proceedings of the Fourth International Symposium on Cyclodextrins (Dordrecht: Kluwer Academic Publishers), pp. 407-413.
82. Szejtli, J. (1983) Dimethyl-beta-cyclodextrin as parenteral drug carrier. J. Incl. Phen. 1, 135-150.
83. Szejtli, J. (1991a) Cyclodextrins in drug formulations. Pharm. Technol. Int., 2, 15-22.
84. Szejtli, J. (1991b) Cyclodextrins in drug formulations. Pharm. Technol. Int., 3, 16-24.
85. Szejtli, J. (1994) Medicinal applications of cyclodextrins. Med. Res. Rev., 14, 353-363.
86. Thompson, D.O. (1997) Cycodextrins - Enabling Excipients: Their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carr. Syst., 14, 1-104.
87. Tötterman, A.M., Schipper, N.G.M., Thompson, D.O. and Mannermaa, J.P. (1997) Intestinal safety of water-soluble β-cyclodextrins in paediatric solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells. J. Pharm. Pharmacol., 49, 43-48.
88. Trinadha, C., Pitlia, J., Lindberg, B. and Lindberg, J. (1992) Distribution of substituents in O-(2-hydroxypropyl) derivatives of cyclomalto-oligosaccharides (cyclodextrins): Influence of increasing substitution, of the base used in the preparation, and of macrocyclic size. Carbohydrate Research, 233, 99-107.
89. Uekama, K. and Otagiri, M. (1987) Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carr. Syst., 3, 1-40.
90. Van de Donk, H.J.M., Zuidema, J. and Merkus, F.W.H.M. (1982) Correlation between the sensitivity of the ciliary beat frequency of human adenoid tissue and chicken embryo tracheas for some drugs. Rhinology, 20, 81-87.
91. Watanabe, Y., Matsumoto, Y., Kawamoto, K., Yazawa, S. and Matsumoto, M. (1992) Enhancing effects of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem. Pharm. Bull., 40, 3100-3104.
92. Watanabe, Y., Matsumoto, Y., Yamaguchi, M., Kikuchi, R., Takayama, K., Nomura, H., Maruyama, K. and Maisumoto, M. (1993) Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and blood leukocyte dynamics following intranasal administration in rabbits. Biol. Pharm. Bull., 16, 93-95.
93. Watanabe, Y., Matsumoto, Y., Kikuchi, R., Kiriyama, M., Ito, R., Matsumoto, M., Nomura, H. and Maruyama, K. (1994) Absorption and blood leukocyte dynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) from intranasally administered preparations containing rhG-CSF and cyclodextrins in rabbits. Int. J. Pharm., 110, 93-97.
94. Yamamoto, M., Yoshida, A., Hirayama, F. and Uekama, K. (1989) Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics. Int. J. Pharm., 46, 217-222.
95. Yancey, P.O., Rodrigueza, W.V., Kilsdonk, E.P.C., Stoudt, G.W., Johnson, W.J., Phillips, M.C. and Rothblat, G.H. (1996) Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J. Biol. Chem., 271, 16026-16034.
96. Yeagle, P.L. (1985) Cholesterol and the cell membrane. Biochem. Biophys. Acta, 822, 267-287.
97. Yoshida, A., Arima, H., Uekama, K. and Pitha, J. (1988) Pharmaceutical evaluation of hydroxyalkyl ethers of beta-cyclodextrins. Int. J. Pharm., 46, 217-222.